Filters close
5-Dec-2024 10:20 AM EST
Almost Half of Young Vapers Are Able to Stop with Quitline Help
Ohio State University

Quitline coaching over the phone helped almost half of young people who vape ditch the habit, potentially improving their health and decreasing the chances they’ll transition to cigarettes, according to a new Ohio State study.

9-Dec-2024 3:00 PM EST
After a Divisive Election, Most U.S. Adults Ready to Avoid Politics This Holiday
American Psychological Association (APA)

A majority of U.S. adults hope to avoid political discussions during the holidays and, in some cases, family members they disagree with, according to a survey by the American Psychological Association.

Newswise: ASH Presentation: Study Shows That Genetic Mutations Accumulate in Smokers with Myelodysplastic Syndromes and Worsen Outcomes
6-Dec-2024 5:00 PM EST
ASH Presentation: Study Shows That Genetic Mutations Accumulate in Smokers with Myelodysplastic Syndromes and Worsen Outcomes
Sylvester Comprehensive Cancer Center

Smokers with myelodysplastic syndromes or a precursor condition had elevated levels of genetic mutations linked to the disease. The study also found that heavier smokers accumulated more mutations, and long-term smokers were more likely to show disease progression.

Newswise: EMBARGOED: Dozens of Presentations Advance Multiple Myeloma Research at the 2024 American Society for Hematology (ASH) Meeting
6-Dec-2024 5:40 PM EST
EMBARGOED: Dozens of Presentations Advance Multiple Myeloma Research at the 2024 American Society for Hematology (ASH) Meeting
Sylvester Comprehensive Cancer Center

Patients with multiple myeloma are living longer thanks to a host of new immunotherapies and targeted drugs. But there is still no cure for the disease. Physician-scientists at Sylvester Comprehensive Cancer Center are working to change that, and will present research findings at the 2024 annual meeting of the American Society of Hematology (ASH).

Released: 9-Dec-2024 8:00 PM EST
ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias
University of Texas MD Anderson Cancer Center

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The results were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. More information on all ASH Annual Meeting content from MD Anderson can be found at MDAnderson.org/ASH.

Newswise: Bringing Dark Comets to Light
Released: 9-Dec-2024 7:35 PM EST
Bringing Dark Comets to Light
Michigan State University

Where did Earth’s water come from? It’s a fundamental scientific question that has never been answered. In fact, NASA reports that we can only observe and understand 5% of the universe — with a whopping 95% remaining a complete mystery because of unobservable dark matter and dark energy.

Newswise: Could Venetoclax Improve Outcomes of CAR T for Patients with Resistant B-Cell Lymphomas? New Insights at ASH
9-Dec-2024 7:30 PM EST
Could Venetoclax Improve Outcomes of CAR T for Patients with Resistant B-Cell Lymphomas? New Insights at ASH
Roswell Park Comprehensive Cancer Center

About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax. Their findings, to be presented during a talk today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California, provide strong preclinical evidence that adding venetoclax to standard treatment may improve outcomes in patients with treatment-resistant B-cell lymphomas.

UNREVIEWED

Newswise: Could US-style Summer Holiday Programs Boost Aussie Kids’ Health?
Released: 9-Dec-2024 7:10 PM EST
Could US-style Summer Holiday Programs Boost Aussie Kids’ Health?
University of South Australia

As the school year winds up, thousands of Aussie kids are looking forward to the summer holidays. But hand-in hand with this freedom comes an abundance of screentime, unhealthy snacks, and a lack of routine, and it has the potential to affect children’s physical and mental health.

Newswise: New Members Named to CSUF Philanthropic Foundation Board of Governors
Released: 9-Dec-2024 6:55 PM EST
New Members Named to CSUF Philanthropic Foundation Board of Governors
California State University, Fullerton

Community leaders and entrepreneurs are among the newest members of Cal State Fullerton’s Philanthropic Foundation Board of Governors, the nonprofit auxiliary organization established to build and strengthen CSUF’s relations with the community and encourage advocacy, investment in and support of the university.

   
Newswise: Toxoplasma Gondii Parasite Uses Unconventional Method to Make Proteins for Evasion of Drug Treatment
Released: 9-Dec-2024 6:05 PM EST
Toxoplasma Gondii Parasite Uses Unconventional Method to Make Proteins for Evasion of Drug Treatment
Indiana University

A study sheds new light on how Toxoplasma gondii parasites make the proteins they need to enter a dormant stage that allows them to escape drug treatment.

Newswise: Four Argonne Researchers Recognized on the American Nuclear Society’s ​“40 Under 40” List
Released: 9-Dec-2024 6:05 PM EST
Four Argonne Researchers Recognized on the American Nuclear Society’s ​“40 Under 40” List
Argonne National Laboratory

Dave Grabaskas, Paul Romano, Ben Lindley and April Novak are recognized by American Nuclear Society on Nuclear News’ highly selective list of rising stars in nuclear research

Released: 9-Dec-2024 5:45 PM EST
ASH: Monoclonal Antibody Therapy Improves Survival in Cancer-Associated Hyper-Inflammatory Disorder
University of Texas MD Anderson Cancer Center

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.

Newswise: Lighting Campus for Hope: A Winter Wonderland of Resilience and Community
Released: 9-Dec-2024 5:00 PM EST
Lighting Campus for Hope: A Winter Wonderland of Resilience and Community
Texas Tech University Health Sciences Center El Paso

More than just a holiday gathering, this free, family-friendly event marked the culmination of a year-long appeal that raised $255,000 to provide 1,350 life-saving cancer screenings in our Borderplex community. Every dollar from event sponsorships will directly support cancer screenings and diagnostics, emphasizing the transformative impact of early detection and care.

Not for public release

This news release is embargoed until 9-Dec-2024 5:00 PM EST Released to reporters: 3-Dec-2024 2:00 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 9-Dec-2024 5:00 PM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Not for public release

This news release is embargoed until 9-Dec-2024 5:00 PM EST Released to reporters: 3-Dec-2024 2:00 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 9-Dec-2024 5:00 PM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Speedy Nuclei Do the Twist
Released: 9-Dec-2024 4:55 PM EST
Speedy Nuclei Do the Twist
Department of Energy, Office of Science

The way hydrocarbon molecules interact with light can affect the production of nitrous acid in the atmosphere. In this study, researchers used an ultrafast electron camera to image the motions of hydrocarbon molecules at ultrafast, ultrasmall scales. They identified a proton transfer step followed by an out-of-plane twisting motion as key components of energy relaxation after molecules interact with light.

Newswise: 20231101_Amarillo_MM_1781.jpg
Released: 9-Dec-2024 4:50 PM EST
Controlling Infectious Disease Between Wildlife and Livestock on Shared Rangeland
Texas A&M AgriLife

Sapna Chitlapilly Dass, Ph.D., assistant professor in microbial ecology and microbiome interactions, Department of Animal Science, is studying the ongoing threat of emerging pathogens that can necessitate prompt deployment of medical countermeasures for life-saving interventions.

   
Newswise: Behind the Model: Visualizing SoLID with 3D Printing
Released: 9-Dec-2024 4:25 PM EST
Behind the Model: Visualizing SoLID with 3D Printing
Thomas Jefferson National Accelerator Facility

Jian-ping Chen, Jefferson Lab Hall A and C Staff Scientist and SoLID Project Manager, and his team created a 3D-printed model of the Solenoidal Large Intensity Device (SoLID) project. Here’s why.

Newswise: DELPHI Symposium Brings Together Data Explorers to Improve Health Care
Released: 9-Dec-2024 4:20 PM EST
DELPHI Symposium Brings Together Data Explorers to Improve Health Care
University of Utah Health

Almost a third of all new electronic data being generated is produced by health care systems. This immense quantity of data has the potential to transform our understanding of biology and drastically enhance health care. But it remains a largely untapped resource, its size and complexity vastly outstripping human intuition.

Newswise: Children’s Hospital of Philadelphia Researchers Find Precision Medicine Treatment Delivers Strong Results for Infantile Fibrosarcoma and Other Solid Tumors
Released: 9-Dec-2024 4:15 PM EST
Children’s Hospital of Philadelphia Researchers Find Precision Medicine Treatment Delivers Strong Results for Infantile Fibrosarcoma and Other Solid Tumors
Children's Hospital of Philadelphia

Researchers at Children’s Hospital of Philadelphia (CHOP) and the Children’s Oncology Group (COG) found that larotrectinib, an oral drug that stops cancer-cell growth, was highly effective in pediatric patients with newly diagnosed infantile fibrosarcoma (IFS) or other solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation. The study, published today in the Journal of Clinical Oncology, is the first COG trial to test precision medicine in a front-line setting across all different types of solid tumors based on a genetic biomarker rather than histology. It is poised to redefine the approach to treatment for newly diagnosed fibrosarcoma and other solid tumors with the NTRK gene fusion, potentially reducing or eliminating the need for these patients to receive chemotherapy.



close
0.14309